Clinical Trial Update: Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated Racotumomab immunotherapy versus supportive care in patients with advanced non-small cell lung cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Racotumomab (racotumomab)

Snippet

Sponsor: Laboratorio Elea Phoenix S.A. | Conditions: Advanced Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED